RT Book, Section
A1 Bauer, Larry A.
SR Print(0)
ID 1106304110
T1 Levetiracetam
T2 Applied Clinical Pharmacokinetics, 3e
YR 2015
FD 2015
PB McGraw-Hill Medical
PP New York, NY
SN 9780071794589
LK accesspharmacy.mhmedical.com/content.aspx?aid=1106304110
RD 2024/04/24
AB Levetiracetam  is  a  pyrrolidine-based  compound  effective  in  the  management  of  partial  and  tonic-clonic  seizures,  and  it  is  administered  as  the  S-enantiomer  of  a  stereoisomer  pair  (Table  16-1).1,2,3,  and  4  It  is  also  useful  for  the  treatment  of  myoclonic  seizures  in  patients  with  juvenile  myoclonic  epilepsy.  Levetiracetam  does  not  exhibit  antiseizure  properties  in  all  models  used  to  screen  antiepileptic  drugs,  and  its  exact  mechanism  of  action  is  largely  unknown.  It  does  bind  to  a  synaptic  vesicle  protein,  SV2A,  present  in  brain  tissue,  and  this  action  is  thought  to  be  important  to  its  therapeutic  actions.5,6